# US 2012/0251637 A1 · Abuse-proofed dosage form

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251637 A1
- Document ID: US20120251637A1
- Status: Published application
- Kind: A1
- Application number: 13/517,891
- Filed: 2012-06-14
- Published: 2012-10-04
- Earliest claimed: 2003-08-06
- Assignees: Gruenenthal GmbH
- Inventors: Johannes BARTHOLOMÄUS; Heinrich KUGELMANN; Elisabeth ARKENAU-MARIC
- Web page: https://patentgrep.com/patent/US20120251637A1

## CPC

- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/205: {Polysaccharides, e.g. alginate, gums; Cyclodextrin}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2068: {Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/2013)}
- A61K 9/2095: {Tabletting processes}
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 31/515: Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/22: Anxiolytics
- A61P 25/30: for treating abuse or dependence
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof.

## Claims

### Claim 1

An abuse-proofed, thermoformed dosage form comprising one or more active ingredients with abuse potential (A) optionally together with physiologically acceptable auxiliary substances (B), at least one synthetic or natural polymer (C) and optionally at least one wax (D), wherein component (C) exhibits a breaking strength of at least 500 N.

### Claim 2 (depends on 1)

A dosage form according to claim 1, which is in the form of a tablet.

### Claim 3 (depends on 1)

A dosage form according to claim 1, which is in multiparticulate form.

### Claim 4 (depends on 1)

A dosage form according to claim 1, wherein the polymer (C) is at least one polymer selected from the group consisting of polyethylene oxide, polymethylene oxide, polypropylene oxide, polyethylene, polypropylene, polyvinyl chloride, polycarbonate, polystyrene, polyacrylate, copolymers and mixtures thereof.

### Claim 5 (depends on 1)

A dosage form according to claim 1, wherein the polymer (C) has a molecular weight of at least 0.5 million according to rheological measurements.

### Claim 6 (depends on 5)

A dosage form according to claim 5, wherein the molecular weight is 1-15 million.

### Claim 7 (depends on 1)

A dosage form according to claim 1, which comprises the wax (D) and the wax (D) is at least one natural, semi-synthetic or synthetic wax with a softening point of at least 60° C.

### Claim 8 (depends on 7)

A dosage form according to claim 7, wherein the wax (D) is carnauba wax or beeswax.

### Claim 9 (depends on 1)

A dosage form according to claim 1, wherein the component(s) (C) is/are present in quantities such that the dosage form has a breaking strength of at least 500 N.

### Claim 10 (depends on 1)

A dosage form according to claim 1, wherein the active ingredient (A) is at least one active ingredient selected from the group consisting of opiates, opioids, tranquillisers, stimulants, barbiturates and further narcotics.

### Claim 11 (depends on 1)

A dosage form according to claim 1, which additionally comprises at least one of the following components a)-f):
(a) at least one substance which irritates the nasal passages and/or pharynx,
(b) at least one viscosity-increasing agent, which, with the assistance of a necessary minimum quantity of an aqueous liquid, forms a gel with the extract obtained from the dosage form, which gel optionally remains visually distinguishable when introduced into a further quantity of an aqueous liquid,
c) at least one antagonist for the active ingredient or active ingredients with abuse potential,
(d) at least one emetic,
(e) at least one dye as an aversive agent,
(f) at least one bitter substance.

### Claim 12 (depends on 11)

A dosage form according to claim 11, wherein the component (a) irritant substance causes burning, itching, an urge to sneeze, increased formation of secretions or a combination of at least two of these stimuli.

### Claim 13 (depends on 12)

A dosage form according to claim 12, wherein the component (a) irritant substance is based on one or more constituents of at least one hot substance drug.

### Claim 14 (depends on 13)

A dosage form according to claim 13, wherein the hot substance drug is at least one drug selected from the group consisting of Allii sativi bulbus (garlic), Asari rhizoma cum herba (Asarum root and leaves), Calami rhizoma (calamus root), Capsici fructus (capsicum), Capsici fructus acer (cayenne pepper), Curcumae longae rhizoma (turmeric root), Curcumae xanthorrhizae rhizoma (Javanese turmeric root), Galangae rhizoma (galangal root), Myristicae semen (nutmeg), Piperis nigri fructus (pepper), Sinapis albae semen (erucae/white mustard seed), Sinapis nigri semen (black mustard seed), Zedoariae rhizoma (zedoary root) and Zingiberis rhizoma (ginger root).

### Claim 15 (depends on 13)

A dosage form according to claim 13, wherein the constituent of the hot substance drug is an o-methoxy(methyl)phenol compound, an acid amide compound, a mustard oil or a sulfide compound or is derived from such a compound.

### Claim 16 (depends on 13)

A dosage form according to claim 13, wherein the constituent of the hot substance drug is at least one constituent selected from the group consisting of myristicin, elemicin, isoeugenol, β-asarone, safrole, gingerols, xanthorrhizol, capsaicinoids, piperine, glucosinolates, and a compound derived from these constituents.

### Claim 17 (depends on 11)

A dosage form according to claim 11, wherein component (b) is at least one viscosity-increasing agent selected from the group consisting of microcrystalline cellulose with 11 wt. % carboxymethylcellulose sodium (Avicel® RC 591), carboxymethylcellulose sodium (Blanose®, CMC-Na C300P®, Frimulsion BLC-5®, Tylose C300 P®), polyacrylic acid (Carbopol® 980 NF, Carbopol® 981), locust bean flour (Cesagum® LA-200, Cesagum® LID/150, Cesagum® LN-1), citrus pectin (Cesapectin® HM Medium Rapid Set), waxy maize starch (C*Gel 04201®), sodium alginate (Frimulsion ALG (E401)®), guar flour (Frimulsion BM®, Polygum 26/1-75®), iota carrageen (Frimulsion D021®), karaya gum, gellan gum (Kelcogel F®, Kelcogel LT1000), galactomannan (Meyprogat 150®), tara bean flour (Polygum 43/1®), propylene glycol alginate (Protanal-Ester SD-LB®), sodium hyaluronate, apple pectin, pectin from lemon peel, sodium hyaluronate, tragacanth, tara gum (Vidogum SP 200®), fermented polysaccharide welan gum (K1A96) and xanthan gum (Xantural 1800).

### Claim 18 (depends on 11)

A dosage form according to claim 11, wherein component (c) is at least one opiate or opioid antagonist selected from the group consisting of naloxone, naltrexone, nalmefene, nalid, nalmexone, nalorphine, naluphine and a corresponding physiologically acceptable compound.

### Claim 19 (depends on 11)

A dosage form according to claim 11, wherein the component (c) is at least one neuroleptic stimulant antagonist.

### Claim 20 (depends on 11)

A dosage form according to claim 11, wherein the component (d) emetic is based on one or more constituents of radix ipecacuanha (ipecac root) and/or is apomorphine.

### Claim 21 (depends on 11)

A dosage form according to claim 11, wherein component (e) is at least one physiologically acceptable dye.

### Claim 22 (depends on 11)

A dosage form according to claim 11, wherein component (f) is at least one bitter substance selected from the group consisting of aromatic oils, fruit aroma substances, denatonium benzoate and mixtures thereof.

### Claim 23 (depends on 11)

A dosage form according to claim 11, wherein the active ingredient or active ingredients (A) is/are spatially separated from component (c) and/or (d) and/or (f), wherein the active ingredient or active ingredients (A) is/are optionally present in at least one subunit (X) and components (c) and/or (d) and/or (f) is/are present in at least one subunit (Y), and, when the dosage form is correctly administered, components (c) and/or (d) and/or (f) from subunit (Y) do not exert their effect in the body and/or on taking.

### Claim 24 (depends on 1)

A dosage form according to claim 1, which comprises at least one active ingredient at least partially in controlled release form.

### Claim 25 (depends on 24)

A dosage form according to claim 24, wherein each of the active ingredients with abuse potential (A) is present in a controlled release matrix.

### Claim 26 (depends on 25)

A dosage form according to claim 25, wherein component (C) and/or component (D) also serve as a controlled release matrix material.

### Claim 27 (depends on 1)

A process for the production of a dosage form according to claim 1, comprising:
mixing components (A), (B), (C) and the optionally present component (D) and the optionally present components (a) to (f) to form a resultant mixture, and
press-forming the resultant mixture, optionally after granulation, to yield the dosage form with preceding, simultaneous, or subsequent exposure to heat.

### Claim 28 (depends on 27)

A process according to claim 27, wherein granulation is performed by means of a melt process.

### Claim 29 (depends on 27)

A process according to claim 27, which comprises press-forming the resultant mixture to yield a press-formed product, and exposing the press-formed product to heat to yield the dosage form.

### Claim 30 (depends on 27)

A dosage form obtainable by a process according to claim 27.

### Claim 31 (depends on 29)

A dosage form obtainable by a process according to claim 29.

### Claim 32

An abuse-proofed, thermoformed dosage form in the form of a tablet obtained by a process comprising:
a) mixing:
i) an opioid or a physiologically acceptable salt thereof;
ii) optionally physiologically acceptable substances (B);
iii) at least one polyalkylene oxide (C) having a molecular weight of 1-15 million according to rheological measurements; and
iv) optionally at least one wax (D);
to form a resultant mixture;
b) pressing forming the resultant mixture to form a press-formed product; and
c) exposing the press-formed product to heat to yield the dosage form.

### Claim 33 (depends on 32)

A dosage form according to claim 32, wherein the opioid or physiologically acceptable salt thereof is oxycodone or a physiologically acceptable salt thereof.

### Claim 34 (depends on 1)

A method of treating a therapeutic condition in a patient suffering therefrom, said method comprising administering to said patient a dosage form according to claim 1.

### Claim 35 (depends on 34)

A method according to claim 34, wherein the therapeutic condition is pain.

### Claim 36 (depends on 32)

A method of treating a therapeutic condition in a patient suffering therefrom, said method comprising administering to said patient a dosage form according to claim 32.

### Claim 37 (depends on 36)

A method according to claim 36, wherein the therapeutic condition is pain.
